Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Antitumor efficacy and safety of a panitumumab-based regimen in colorectal cancer

Nov. 25, 2004

MT-201 cleared to enter phase II U.S. trial in metastatic breast cancer

Nov. 25, 2004

Alfacell and NCI pursue development of RN-321

Nov. 24, 2004

First clinical data reported for IGN-311 in solid tumors overexpressing Lewis Y antigen

Nov. 19, 2004

Positive phase II data with HspE7 in high grade cervical dysplasia

Nov. 19, 2004

Pivotal study of MyVax Personalized Immunotherapy recommended to continue

Nov. 19, 2004

Raven files IND for phase I study of RAV-12 in advanced adenocarcinoma

Nov. 18, 2004

Lorus signs Virulizin supply agreement with BioVectra

Nov. 18, 2004

A specific cancer vaccine increases survival of patients with advanced NSCLC

Nov. 15, 2004

HER-2 Protein AutoVac breast cancer vaccine enters phase II

Nov. 15, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 4, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...